Skip to main content
. 2007 May 8;96(11):1692–1698. doi: 10.1038/sj.bjc.6603776

Table 2. Incidence of selected adverse events: first cycle, all causalities.

  120 mg m−2 (n=3) 140 mg m−2 (n=3) 160 mg m−2 (n=6) 180 mg m−2 (n=3)
Grade (NCIC-CTC) All/grade 3–4 All/grade 3–4 All/grade 3–4 All/grade 3–4
Blood/bone marrow
 Haemoglobin 2/0 2/0 5/1 2/1
 Platelets 1/0 2/0 3/0 3/2
 Leukocytes 0/0 1/0 3/0 2/1
 Neutrophils 0/0 0/0 1/0 1/1
 Lymphocytes 3/3 3/3 6/6 3/3
 Febrile Neutropaenia 0/0 0/0 0/0 1/1
         
Constitutional symptoms
 Fatigue 2/1 3/1 4/0 1/0
 Allergy 0/0 0/0 0/0 1/0
         
Gastrointestinal
 Nausea 3/0 2/0 2/0 2/0
 Vomiting 2/0 2/0 1/0 1/0
 Aiorejia 1 /1 2/0 3/0 2/0
 Constipation 0/0 1/0 0/0 1/0
         
Cholinergic symptoms
 Dry mouth 0/0 0/0 1/0 1/0
         
Cardiovascular symptoms
 Deep vein thrombosis 1/1 1/1 0/0 0/0
 Tachycardia 1/0 1/0 2/0 0/0